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Introduction
This paper prohIe.matizcs polyphar.macy, jnciud.m C.A.M, in the
c.ontex.t of elderly ca.ncer patients Ffi.rther, it re.views the unique
find.ings of studies of C.A\ I use in 1—1 awaii, which offer insights in.to
both the objectives and the measure of CAM use by cancer patients.
and. suggests that this knowledge can he translated in.to i.n.te.grated
clinical practice.
Polypharmacies
Polypharmacy is a coherent preventive and therapeunc strategy in
conventional biomedicine, and is used increasingly in the treatment
of monodrug—resistant and Ire )emergent infections such as malaria,
tuberculosis, and cholera (Fanner I Sheld et al. 1998: Scior et
al. 2002). Multi-drug regimens also ma\ he effective for disorders
for which a substantial proportion of patients experience no or in
complete response to singlet drugs
- e.g.. eardios aseular disorders,
hypertension, and epi lepsv (Campos—Castello and Campos—Soler
2004: Ga ras and Rosenthal 2004. Today, the term pol\ pharmac
extends to multiple prescriptions I mm more than one physician, as
well as to patieni—cratied combinations of prescription drugs. and
drugs with other therapeutic modalities. In a more conventional
delinition. polvpharmacy is mdicated for co—morhidities. for which
the elderly are at especial l\ high risk.
Polypharmacy among the Elderly
In the [.5. and western Europe the elderl comprise I SC -20C of
the population hut account <or 30—41P of all drug prescriptions. An
estimated OOC ot’cominunii -dwelling olderadults rake at least one
prescription, most take two or more: nursing—home. variably assisted—
living’, and hospitalized elderl typically take six to nine prescription
drugs. Older adults also purchase about SOC of over—the—counter
producis (Clews ci al. 2001: Curcoran 1007: Paille 20(34: PoIlock
1998<. Polvpharmac\ among the eldcrl\ is further contounded b
the use iii complcnientar and alternative medicines, for virtually
all age—associated conditions. Estimated rates of consumption range
hetu ecu 5<)’ and 0O’.
While polypharmac offers benefits in some clinical contexts, it
constitutes substantial risk for all patients, and especially for the
elderly. Beginning at about 40 sears of age, individuals experience
a linear decline in a number of physiologic functions, which can
affect pharmacokinetic and pharmacodynamic processes. Possible
undesired outcomes of -- singlet and especially multiple — drug
consumption include altered drug distribution and activity, delayed
and extended-duration ettects, and changes in the processes of drug
metabolism and detoxification, Polypharmacy s.ign.ificantly in.creases
th.e. ,r,is:k and sevcrit\ of’ adverse, drug reactions (A.’D’Rs) wh.ich cor
relate. directly and exponentially with the. number, and number of
kinds, of drugs taken and the number of prescribing physicians.
The rate of.ADRs among, older adults is two to seven times hig.,he.r
than for other age sectors (Koda-Kimble and Young 2001 ).
The annual cost of age-associated drug-related problems is enor
mous and is compounded by psychological and social disjunctions.
Polypharmacy fosters confusion: many elderly have difficulty keep
ing track of multiple medications, especially those with different
hut overlapping dosing schedules: anxiety about toxicity and ADRs
increases incrementall’s ‘n ith added prescriptions. This resonates
especially for elderl whose memor of fewer medicines is more
vivid than their short-term experience with current prescriptive
practices. These and other concerns contribute to invoking other
cultural constructions of health arid healing that are discrepant with
biomedical paradigms. and include actions that may be interpreted
h\ biomedicine as “noncompliance. One potent expression of
patient—drix en strategies is sell’— or home—treatment, including the
cisc of complementar and alternati\ e medicine. (CAvI
Cancers, Polypharmacy, and CAM
An II —fdld greater incidence, and more than half of cancers, occur
in indi iduals aged 65 ‘ears or older, among whom the greater
likelihood of co—niorhidits. coupled s ith the comple.x nature 01”
cancer therapies. encourages polypharmacy I Al—Shahri ci al. 20(33:
Lichtman 2003: Tenet 2004<. including self— or home—treatment.
Like its pharmaceutical counterpart. the CAM industry maximizes
profit h\ making available a multiplicity of products that both till
and create niches of ‘‘need.’’ Patients command agenc’ in theirossn
health care by purchasmnu these pi’oduets. and through their social
transaction create and transform the meaning of the therapeutic
c\pemience. .-\ great anet of (‘AM are promoted speciticaIl for
the presention and tm’catment of cancers. ss oh estimates oICAN’I use
h\ cancer patients ranging as high as X5 . CAM typically are used
to supplement cheniotherapies and for the treatment of side effects
of cancer and cancer therapies: only a small percentage of cancer
patients use (‘AM as an alternative to biomedical treatments.
Cancer and (‘AM in 1-lawail
OurstudiesofCAM use in Honolulu, Hawaii (Etkin etal, 1999: Etkin
and McMillen 2003)’ explored in depth the cultural constructions
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of health and healing in a demographically diverse population, and
documented 346 discrete CAM products or processes. Seventy-live
percent of(AM reported by study participants are hotanicals, \vhich
range from treatments for sped tic disorders such as hs perterision
to more general objecti es such as ‘‘general health’’ We further
retincd the research methodologs and scope in a subsequent study
that locused on hospitaliied and out—patients in the oncology unit
ot a major medical center in Honul Lii Li hi kin and Ross 201)2).
Our research establishes thai cancer patients in Honolulu use a
\‘ ide range of CAM and corroborates the findings of other studies ol
(‘AM use in Hawaii and \orth America. Those other studies ss crc
based on surs cvs rather than in—depth interviews, and are largely
descriptis c. Our studies add ethnographic depth to re cal how the
popularity of CAM is both market-driven and culturally—constructed.
The cummodification and aggressi\ e marketing of contemporarr
culture extends to health care and (‘AM, and encourages consumers
to “shop around,” Among the pre entive and healing metaphors thai
guide the interpretation of illness, the ideaof’holistic’ (whole-both
healing extends beyond the individual to the community and the
ens ironment—healthy land, health community, healthy individuals,
As theirexperience with cancers increased study partic ipants’conccrn
for the toxicity of chemotherapy. ther were drawn to botanical CAM
on the shared perception that “natural” products are safe, Especiallr
compel lute for elderly cancer patients are commercial CAM that
ads crtisc “cleansing” and “imiiiuuc hoo5tinc” properties. 1 hesc
and related terms fee,, “cholesiei’ol-lowering,” “antioxidant that
ha e dirt used into the vernacular through advertising and popular
science media are apprehended hr the public cmiv as somethnig
healthful. without specilic information about how to measure the
presence or efiicacr of these qualities.
0 “tiid\ I irtlclpant used CAM as an al ternat v c to clenit t— and
other hioihcrapies: most soucht CAM to strengthen themsels C’s and
to manage the anticpatcd orcxpercnccd side effects entional
treatments. Our research con Ii rmed the image commonly projected in
the CAM literature (eg, Keluer ci af 2(104: Richardson et al 2004
that oncologists and patients has e discrepant views about theefficac\
and potential risk of CAM, However, ss bile study participants were
not nchned to discuss CAM with physicians, they are respectful of
their advice and, significantly, would welcome health professionals
in a resource role for CAM information, By now, the allied health
proUssions have a’pprehendel just how many patients use CAM
and the diversity of products available. Biomedical professionals
who do try to engage their patients on the subject of CAM Coifle to
appreciate how i.ittie i.eliahle in formation is avaiiahl.e about CAM
in the context of clinical medcine: .ud there ic growing nterct in
n Lh ‘ix h, n: i ii is itt
C’ \\1 tee., Ben-Arve and Frenkel 2004t.
[he ii nd in es of both of our st ui , cc reinforce the unportanee ‘f
poir phu rmacs, The risk of ADRs amone pharmaceuticals has been
impl\ demonstrated, and while es deuce documcutiue the posihil
tx tfADRs r’etxxeeu CAM and pharmaceuticals is iimitu’d Biciirr
“(04 Lix in—Lewis 2fH’il : S patehsnn ct al. 2001, the’ theoretical
ni’,sihil:tics ‘c high. Oulr a xer\ rn,til pcrcentaeeo cii (‘AM
cu i ii chn II ti u ii ii a
of the commercial products is subjected to standardization or other
regulation (contrary to what mailr et usumers believe, CAM inc not
I cl h th U S Food ml Di u \dmuistratmon) (onqu utl’
even some of the commercial products that contain botanicals tlt it
has e hecn well characterized phr tochemicalls aie not reliable,
Conclusion
The sLibte vt h, re is not that C’ \ \1 arc ‘S ithout benetit Indeed, the
scientific literature ethnopharmacoloer pharmacognosr and
phs tochemi’trv suggests significant phai’macoloeic potential I he
ponit is that in the contest 0 comples phr siian—dr is en and patient
augmented polr pharmac. the potential tor ADRs is high. ‘I hi
stak ment implicates pharmaceuticals as much a it does xx hat e
mi”ht eventual Ir knoss about C AM, ilth ugh one could argue th ir
pharmacc uncal s w ill alss as s pose a i eatei i isk m s iexx f the hi ehem
poteimc\ an I conc enti’ation ot aeti xc cons ituents ilk docuniciitcu
risks of ADRs ‘n phai maceutical polx’pharm’tcs nt eon junctioi
with th xx ide pie d and apparently orox ‘to usc of C \\I ohcr
cc) uipcllin troumet t to g nei’ate lime’ llv n e’t inof t data on th
pfo ic loni implications f usino CA, I d tr msl ite th’ t intorn
ti mt ‘ute’ t d limed pi lett
F )i mm nforn tiononthe ‘n rRc bCe t fl-Iass
placvt t m xv hsic’itsxssvxerh,or
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